Gene or Genome – Page 18 – Talk Bio

Actionable Insights Powered by AI

FDA Delays Decision on Merus’ Zenocutuzumab for NRG1+ Lung and Pancreatic Cancer

10 months ago talkbio0Tagged Antibodies, Bispecific, Deferred, Malignant neoplasm of lung, Malignant Neoplasms, Merus, NRG1 gene, Pancreatic carcinoma, United States Food and Drug Administration, zenocutuzumab

Zenocutuzumab, NRG1+ cancer, FDA delay, Merus, lung cancer, pancreatic cancer, bispecific antibody.

Kymera Therapeutics Shifts Focus to Immunology, Scaling Back Oncology Efforts

10 months ago talkbio0Tagged Immunology, IRAK4 gene, Kymera, Neoplasms, Protein Degradation, Metabolic, STAT6, TYK2 gene

Kymera Therapeutics, Immunology, Oncology, Targeted Protein Degradation, IRAK4, STAT6, TYK2

Axonis Secures $115 Million to Develop Novel Treatment for Drug-Resistant Pain and Epilepsy

11 months ago talkbio0Tagged Axonis, CNS disorder, drug-resistant pain, Epilepsy, GABA-related, Psychological inhibition, SLC12A5 gene

Axonis Therapeutics, drug-resistant pain, epilepsy, CNS disorders, KCC2, GABA-related inhibition, series A funding

TCT 2024: Johnson & Johnson’s Abiomed Successfully Completes Pivotal Study for Innovative Shrinkable Heart Pump, Impella ECP

11 months ago talkbio0Tagged Abiomed, Approved, High-Risk PCI, Impella, Johnson & Johnson, RNASE3 gene, Shock, Cardiogenic, Shrinkable Heart Pump, Thrombin Time Assay, United States Food and Drug Administration

TCT 2024, Johnson & Johnson, Abiomed, Impella ECP, Shrinkable Heart Pump, High-Risk PCI, Cardiogenic Shock, FDA Approval

Novartis Secures FDA Approval for Scemblix as First-Line Treatment for Newly Diagnosed CML, Anticipates $3B in Peak Sales

11 months ago talkbio0Tagged Approved, first-line, Inhibitor, Myeloid Leukemia, Chronic, Novartis, Scemblix, TTLL5 gene, Tyrosine Kinase Inhibitors [MoA], United States Food and Drug Administration

Novartis, Scemblix, FDA Approval, First-Line Treatment, CML, Chronic Myeloid Leukemia, ASC4FIRST Trial, Tyrosine Kinase Inhibitors, STAMP Inhibitor

Revolution Medicines Advances in Pancreatic Cancer Treatment with RMC-6236 and RMC-9805

11 months ago talkbio0Tagged cellular targeting, Clinical Trials, inhibitors, Pancreatic carcinoma, ras Oncogene, Revolution Medicines, RMC-6236, RMC-9805

Revolution Medicines, RMC-6236, RMC-9805, pancreatic cancer, RAS inhibitors, targeted therapies, clinical trials

Roche and Dyno Therapeutics Launch $1B+ Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Neurological Diseases

11 months ago talkbio0Tagged AAVS1 gene, Cloning Vectors, Collaboration, Dyno, gene delivery process, gene therapy, LEAP, Neurological diseases, Roche (company), Technology

Roche, Dyno Therapeutics, AAV gene therapy vectors, Neurological diseases, AI-driven gene delivery, LEAP technology, Gene therapy collaboration

Roche Revisits Dyno for AAV Technology with $50M Upfront Payment

11 months ago talkbio0Tagged AAV, AAVS1 gene, Dyno, gene therapy, Neurological diseases, Roche (company), strategic partnership, Technology

Roche, Dyno Therapeutics, AAV technology, gene therapy, neurological diseases, strategic partnership

ICER Report Suggests Significant Price Reduction for Pfizer’s ATTR-CM Drug Tafamidis

11 months ago talkbio0Tagged ATTR-CM, Cost-Effectiveness, CREM gene, ICER, Pricing, tafamidis

Tafamidis, ATTR-CM, ICER, Pricing, Cost-Effectiveness

FDA Delays Decision on Amgen’s Lumakras and Vectibix Combination for Metastatic Colorectal Cancer

11 months ago talkbio0Tagged amgen, G12C mutation, K-ras Oncogene, Lumakras, Metastasis from malignant neoplasm of colon and/or rectum, panitumumab, sotorasib, United States Food and Drug Administration, Vectibix

FDA, Amgen, Lumakras, Vectibix, metastatic colorectal cancer, KRAS G12C mutation, sotorasib, panitumumab